



Vaccines and Global Health: The Week in Review
21 August 2021 :: Issue 620
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. **This blog allows full text searching of over 23,000 entries.***

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

A. [Milestones :: Perspectives :: Featured Journal Content](#)

B. [Emergencies](#)

C. [WHO; CDC \[U.S., Africa, China\]](#)

D. [Announcements](#)

E. [Journal Watch](#)

Milestones :: Perspectives :: Research

.....
.....

COVID

Editor's Note:

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition:

david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

.....
.....

ACT-Accelerator launches urgent US\$ 7.7 billion appeal to stem surge of dangerous variants and save lives everywhere

16 August 2021 *WHO News release*

- Delta variant on path to become dominant strain worldwide as surge in the highly transmissible variant increases urgency for vaccinating large numbers of vulnerable people
- Rising infection rates resulting in increased hospitalizations are overwhelming health systems and leaving many countries in urgent need of life-saving oxygen
- Testing rates in much of the world is too low, especially low- and lower-middle-income countries [\[1\]](#) – leaving much of the world blind to how the disease is evolving and vulnerable to new variants
- Funding the Rapid ACT-Accelerator Delta Response (RADAR) urgent appeal for US \$7.7 billion would enable: significantly increased testing and better surveillance to detect and protect against new variants; more oxygen to treat the seriously ill and save lives; vital personal protective equipment (PPE) to protect health workers; the rolling out of emergency response and delivery support for the effective delivery and deployment of COVID-19 tools, including in humanitarian contexts; and continued research and development (R&D) so that tools remain effective
- The US\$ 7.7 billion is not an additional funding need but is part of the ACT-Accelerator's overall 2021 budget, which is needed urgently within the next four months

With more COVID-19 cases reported in the first five months of 2021 than in the whole of 2020, **the world is still in the acute phase of the pandemic – despite high vaccination rates in some countries** protecting populations from severe disease and death. **Inadequate testing and low vaccination rates are exacerbating disease transmission and overwhelming local health systems**, while leaving the whole world vulnerable to new variants.

Many countries are experiencing new waves of infections – and while many high-income countries and some upper-middle-income countries have implemented widespread vaccinations, put more robust testing systems in place, and made treatments increasingly available – **many low- and lower-middle-income countries are struggling to access these vital tools due to a lack of funds and supplies. Investing in the ACT-Accelerator to make tools available to everyone, everywhere, will benefit all countries through a more globally inclusive and coordinated response.**

While four variants of concern currently dominate the epidemiology, there are fears that new, and possibly more dangerous, variants of concern may emerge.

With hard-won gains of the last three months at risk, the **ACT-Accelerator has mounted a US\$ 7.7 billion appeal, the Rapid ACT-Accelerator Delta Response (RADAR), to urgently:**

- **Scale up testing:** US\$2.4 billion to put all low- and lower-middle-income countries on track towards a ten-fold increase in COVID-19 testing and ensure all countries get up to satisfactory testing levels. This will significantly enhance local and global understanding of the changing disease epidemiology and emerging variants of concern, inform the appropriate application of public health and social measures and break chains of transmission.
- **Maintain R&D efforts to stay ahead of the virus:** US\$ 1 billion for ongoing R&D, enable further market shaping and manufacturing, technical assistance and demand generation to ensure that tests, treatments and vaccines remain effective against the Delta variant and other emerging variants, and that they are accessible and affordable where they are needed.
- **Address acute oxygen needs to save lives:** US\$ 1.2 billion to rapidly address acute oxygen needs to treat the seriously ill and control the exponential death surges caused by the Delta variant.
- **Rollout of tools:** US\$ 1.4 billion to help countries identify and address key bottlenecks for the effective deployment and use of all COVID-19 tools. As supply of COVID-19 vaccines ramps up in the coming months, flexible funding will be essential to help fill on-the-ground delivery gaps.
- **Protect frontline healthcare workers:** US\$ 1.7 billion to provide two million essential healthcare workers with enough basic PPE to keep them safe while they care for the sick, prevent the collapse of health systems where the health workforce is already understaffed and overstretched, and prevent further spread of COVID-19.

In addition to the US\$ 7.7 billion appeal, there is an opportunity to reserve the supply of vaccines through exercising options in the fourth quarter of 2021 for 760 million doses of vaccine to be available in mid-2022 beyond the fully subsidised doses that COVAX will deliver up to the end of Q1 2022. Commitments to reserve these vaccine options in the last quarter of the year for delivery in the middle of 2022 can be made to Gavi/COVAX, as part of the ACT-A network of agencies.

- **Reserve vaccines:** Reserve supply of 760 million doses of vaccine by exercising options in the final quarter this year to ensure there is continued supply available to make deliveries into 2022. Reserving doses requires contingent capital; on delivery these 760m doses will cost an additional US\$ 3.8 billion...


.....
.....


Multilateral Leaders Task Force on COVID-19 [IMF, World Bank Group, WHO, WTO]

A [joint initiative](#) from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.

Data to help track, coordinate, and advance delivery of COVID-19 health tools to developing countries and to mobilize relevant stakeholders and national leaders to remove critical roadblocks - in support of the priorities set out by the WBG, IMF, WHO, and WTO.

Website accessed **21 Aug 21**: <https://data.covid19taskforce.com/data> The global view below is complemented by country-specific dashboards [here](#).





.....
.....

World Bank Vaccine Operations Portal

<https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines>

As of July 29, 2021, the World Bank approved operations to support vaccine rollout in 54 countries amounting to \$4.6 billion. See the latest project financing, project documents and procurement information in the list below:

[Countries receiving World Bank support for vaccines](#)

As of July 29, 2021

This list of countries, project documents, and procurement notices and contracts will be updated as data becomes available.

.....
.....

COVID Vaccines – OCHA:: HDX

[COVID-19 Data Explorer: Global Humanitarian Operations](#)

COVID-19 Vaccine Roll-out

Aug 21, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 210M total confirmed cases; 4.4M total confirmed deaths
Global vaccines administered: 4.88B**

Number of Countries: 26 [26]

COVAX Allocations (Number of Doses): 73M [73M week ago]

COVAX Delivered (Number of Doses): 53M [46M week ago]

Other Delivered (Number of Doses): 93M [61M week ago]

Total Delivered (Number of Doses): 150M [110M week ago]

Total Administered (Number of Doses): 110M [110M week ago]

.....
.....
.....

Coronavirus [COVID-19] - WHO

Public Health Emergency of International Concern (PHEIC)

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Weekly Epidemiological and Operational updates

Last update: 13 Aug 2021

Confirmed cases :: 209 876 613 [205 338 159 week ago]

Confirmed deaths :: 4 400 284 [4 333 094 week ago]

Vaccine doses administered: 4 562 256 778 [4 428 168 759 week ago]

.....
.....

19 August 2021 *Speech*

[WHO Director-General's opening remarks at the Member State Information Session on COVID-19 - 19 August 2021](#)

18 August 2021 *Speech*

[WHO Director-General's opening remarks at the media briefing on COVID-19 - 18 August 2021](#)

- In Haiti, where the earthquake has killed more than 1,900 people, we are continuing to support the government and the people by all means possible during this difficult moment.
- The people of Afghanistan are facing an enormous challenge. We are particularly concerned about the health and wellbeing of women and girls. Our staff remain in the country and committed to delivering health services to the most vulnerable.
- This week, a new case of Ebola was identified in Côte d'Ivoire. Thousands of doses of Ebola vaccines were sent from Guinea to Cote d'Ivoire and ring vaccination of high-risk contacts has started.
- **Just 10 countries have administered 75 per cent of all vaccine supply and low-income countries have vaccinated barely 2 per cent of their people. I called for a temporary moratorium on boosters to help shift supply to those countries that have not even been able to vaccinate their health workers and at-risk communities and are now experiencing major spikes.**

- **Vaccine injustice is a shame on all humanity and if we don't tackle it together, we will prolong the acute stage of this pandemic for years** when it could be over in a matter of months. When G20 health ministers meet on the 5th and 6th of September in Rome, I will call on them to consider the fragility of this historic moment and make a clear defining commitment to solidarity.

...At present, just 10 countries have administered 75 per cent of all vaccine supply and low-income countries have vaccinated barely 2 per cent of their people.

I called for a temporary moratorium on boosters to help shift supply to those countries that have not even been able to vaccinate their health workers and at-risk communities and are now experiencing major spikes.

Last week, WHO brought together 2,000 experts from all around the world and debated the available data on boosters. What is clear is that it's critical to get first shots into arms and protect the most vulnerable before boosters are rolled out.

The divide between the haves and have nots will only grow larger if manufacturers and leaders prioritise booster shots over supply to low- and middle-income countries. The virus is evolving and it is not in the best interests of leaders just to focus on narrow nationalistic goals when we live in an interconnected world and the virus is mutating quickly.

In fact, strong national leadership would be to fully commit to vaccine equity and global solidarity, which would save lives and slow variants down.

In this context, I was stunned by the news that J&J vaccines fill and finished in South Africa are leaving the continent and going to Europe, where virtually all adults have been offered vaccines at this point.

We urge J&J to urgently prioritize distribution of their vaccines to Africa before considering supplies to rich countries that already have sufficient access...

.....

[Weekly operational update on COVID-19 - 16 August 2021](#)

Overview

In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

- Facilitating procurement of 1.6 million antigen-detecting rapid diagnostic tests to strengthen COVID-19 diagnostic in Indonesia
- The roll-out of Go.Data contact tracing tool in Ukraine
- Donated COVID-19 vaccine doses by France arrive in Somalia
- Community health at the center of COVID-19 vaccination in indigenous communities in Paraguay
- Online learning opportunities to support hospital infection prevention and control committees in Azerbaijan
- Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
- Updates on WHO's financing to support countries in SPRP 2021 implementation and provision of critical supplies.

Weekly epidemiological update on COVID-19 - 17 August 2021


Overview

The global number of new cases has been increasing for the last 2 months with over 4.4 million cases reported in the past week (9 – 15 August 2021), bringing the cumulative number of globally to cases to over 206 million. This increasing trend is largely attributed to increases in the Western Pacific Region and the Region of the Americas which reported 14% and 8% increases respectively as compared to the previous week. Overall, the number of deaths reported remained similar with over 66 000 deaths this week, as compared to the previous week. While the African Region reported the largest percentage decrease in case and death incidence, 23% and 18% respectively, data from the weekend is incomplete which might lead to an overestimation of the percentage change. The Western Pacific and the Eastern Mediterranean Regions reported the highest proportionate increases in death incidence of 23% and 15% respectively over the last seven days.

In this edition, a special focus updates are provided on:

- SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta which includes updates on the geographic distribution of VOCs.
- COVID-19 in Prisons

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 15 August 2021**



.....

Call for experts to join Scientific Advisory Group for the Origins of Novel Pathogens

20 August 2021 *News release*

Issued on: 20 August Deadline: 10 September

The World Health Organization (WHO) today issued an open call for experts to serve as members of the new WHO Scientific Advisory Group for the Origins of Novel Pathogens (SAGO).

The SAGO will advise WHO on technical and scientific considerations regarding the origins of emerging and re-emerging pathogens of epidemic and pandemic potential, and will be composed of a wide range of experts acting in their personal capacity. SAGO will also guide WHO on next steps for understanding the SARS-CoV-2 origins.

There have been an increasing number of high threat pathogens emerging and re-emerging in recent years with, for example, SARS-CoV, MERS-CoV, Lassa, Marburg, Ebola, Nipah, avian influenza, the latest being SARS-CoV-2. There is a clear need for robust surveillance and early actions for rapid detection and mitigation efforts, as well as systematic processes to study the emergence of these pathogens and routes of transmission from their natural reservoirs to humans. This is critical to helping WHO, Member States and partner institutions to prepare for future spillover threats and to minimize the risk of a disease outbreak growing into a pandemic.

From SARS-CoV-2, which continues to wreak havoc around the world, to the next "Disease X", this global framework to study the emergence of new and known high threat pathogens needs to be comprehensive and coordinated based on a One Health approach. It should also encompass biosafety and biosecurity. And it needs to be scientific, transparent, comprehensive, rapid and inclusive...

Functions of SAGO

...4. In the context of SARS-CoV-2 origins:

:: To provide the WHO Secretariat with an independent evaluation of all available scientific and technical findings from global studies on the origins of SARS-CoV-2;

:: **To advise the WHO Secretariat regarding developing, monitoring and supporting the next series of studies into the origins of SARS-CoV-2, including rapid advice on WHO's operational plans to implement the next series of global studies into the origins of SARS-CoV-2, as outlined in the 'Joint WHO-China Global Study of Origins of SARS-CoV-2: China Part' report published on 30 March 2021** and advise on additional studies as needed; and

5. To provide additional advice and support to WHO, as requested by the WHO SAGO Secretariat, which may include participation in future WHO-international missions to study the origins of SARS-CoV-2 or for other emerging pathogens.

...More information can be found on the [Terms of Reference of the SAGO](#) The SAGO will be multidisciplinary, with members who have a range of technical knowledge, field experience, skills and experience relevant to emerging and re-emerging pathogens. Up to 25 experts may be selected...
















.....
.....

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 19 August 2021

For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

[See full scale graphics at link above]

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
1.	 BioNTech Manufacturing GmbH	BNT162b2/COMIRNATY Tozinameran (INN)	EMA	Nucleoside modified mRNA	✓	✓	✓	Finalized: Additional sites: – Baxter Oncology GmbH Germany (DP) – Novartis Switzerland – Milbe (Dermapharm) Germany (DP) Diluent suppliers: – Pfizer Perth, Australia Fresenius Kabi, USA	31/12/2020 30/06/2021 08/07/2021 16/07/2021 18/06/2021
			USFDA				✓	Finalized: – Pharmacia & Upjohn, Kalamazoo (DP) JGS McPherson (DP)	16/07/2021 16/07/2021
2.		AZD1222 Vaxzevria	EMA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Core data finalized	16 April 2021
3.	 AstraZeneca, AB	AZD1222 Vaxzevria	MFDS KOREA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized: Additional sites: – SK-Catalent – WuXi (DS) – Chemo Spain – Amylin Ohio US (DP)	16 April 2021 30 April 2021 04 June 2021 23 July 2021
4.		AZD1222 Vaxzevria	Japan MHLW/PMDA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	09 July 2021
5.		AZD1222 Vaxzevria	Australia TGA	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	09 July 2021
6.									
7.	 Serum Institute of India Pvt. Ltd.	Covishield (ChAdOx1_nCoV-19)	DCGI	Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2.	✓	✓	✓	Finalized	15 Feb 2021
8.	 Janssen-Cilag International NV	Ad26.COV2.5	EMA	Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein	✓	✓	✓	Core data finalized (US +NL sites) Additional sites: – Merck, Durham, UK (DS) – Merck, West Point/PA (DP)	12 March 2021 -25 June 2021 - 02 July 2021 - As submitted - As submitted
9.	 Moderna Biotech	mRNA-1273	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)		✓	✓	Finalized	30 April 2021
			USFDA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	✓	✓	Finalized ModernaTx, Norwood (DS) – Catalent Indiana, LLC (DP) – Lonza Biologics, Inc. Portsmouth, USA (DS) – Baxter, Bloomington, USA (DP)	06 August 2021
10.	 Beijing Institute of Biological Products Co., Ltd. (BIBP)	SARS-CoV-2 Vaccine (Vero Cell), Inactivated (InCoV)	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	07 May 2021
11.	 Sinovac Life Sciences Co., Ltd. Sinovac Life Sciences Co., Ltd.	COVID-19 Vaccine (Vero Cell), Inactivated/Coronavac™	NMPA	Inactivated, produced in Vero cells	✓	✓	✓	Finalized	01 June 2021
12.	 THE GAMALEYA NATIONAL CENTER	Sputnik V	Russian NRA	Human Adenovirus Vector-based Covid-19 vaccine	Additional information submitted	Several meetings have been and continue to be held.	"Rolling" submission incomplete.	On hold, awaiting completion of rolling submission	Anticipated date will be set once all data is submitted and follow-up of inspection observations completed.
13.	 Bharat Biotech, India	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/COVAXIN	DCGI	Whole-Virion Inactivated Vero Cell	✓	✓	Rolling data started 06 July 2021	Ongoing	To be confirmed
14.	 Sinopharm / WIBP ²	Inactivated SARS-CoV-2 Vaccine (Vero Cell)	NMPA	Inactivated, produced in Vero cells	✓	✓	Rolling data started 23 July 2021	Ongoing	To be confirmed
15.	 CansinBio	Ad5-nCoV	NMPA	Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)	✓	✓	Rolling data started 09 August 2021		
16.	 NOVAVAX	NVX-CoV2373/Covovax	EMA	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	✓	Rolling data starting in August 2021		
17.	 SANOFI	CoV2 preS dTM-AS03 vaccine	EMA	Recombinant, adjuvanted	✓	✓	Rolling data started 30 July 2021		
18.	 SERUM INSTITUTE OF INDIA PVT. LTD.	NVX-CoV2373/Covovax	DCGI	Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant.	✓	10 August 2021	Rolling data starting in August 2021		
19.	Clover Biopharmaceuticals	SCB-2019	NMPA	Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein	✓	Being planned			
20.	 CureVac	Zorecimeran (INN) concentrate and solvent for dispersion for injection; Company code: CVnCoV/COV7050101	EMA	mRNA-based vaccine encapsulated in lipid nanoparticle (LNP)	✓	Planned for Q4 of 2021, at request of the applicant.			
21.	Vector State Research Centre of Virology and Biotechnology	EpiVaccCorona	Russian NRA	Peptide antigen	Letter received not EOI. Reply sent on 15/01/2021				

	Manufacturer / WHO EUL holder	Name of Vaccine	NRA of Record	Platform	EOI accepted	Pre-submission meeting held	Dossier accepted for review*	Status of assessment**	Decision date***
22.	Zhifei Longcom, China	Recombinant Novel Coronavirus Vaccine (CHO Cell)	NMPA	Recombinant protein subunit	Response to 2 nd EOI sent 29 Jan 2021. Additional information requested.				
23.	IMBCAMS, China	SARS-CoV-2 Vaccine, Inactivated (Vero Cell)	NMPA	Inactivated	Not accepted, still under initial development				
24.	BioCubaFarma - Cuba	Soberana 01, Soberana 02, Soberana Plus, Abdala	CECMED	SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum	Awaiting information on strategy and timelines for submission.				

1. Beijing Institute of Biological Products Co-Ltd
2. Wuhan Institute of Biological Products Co Ltd

* Dossier Submission dates: more than one date is possible because of the rolling submission approach. Dossier is accepted after screening of received submission.

**Status of assessment: 1. Under screening; 2. Under assessment; 3. Waiting responses from the applicant. 4. Risk-benefit decision 5. Final decision made

*** Anticipated decision date: this is only an estimate because it depends on when all the data is submitted under rolling submission and when all the responses to the assessors' questions are submitted.

Please send any questions you may have to: WHOEL@who.int

.....
.....

COVID Vaccine Developer/Manufacturer Announcements

[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca

Press Releases

[AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19](#)

20 August 2021

:: 77% reduced risk of developing symptomatic COVID-19

:: First long-acting antibody combination to prevent COVID-19

Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial's primary endpoint.

AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo. The trial accrued 25 cases of symptomatic COVID-19 at the primary analysis...

BioCubaFarma – Cuba

Últimas Noticias - *[Website not responding at inquiry; receiving 403=Forbidden message]*

CanSinoBIO

News - *[Website not responding at inquiry]*

Clover Biopharmaceuticals - China

News - *No new digest announcements identified*

Curevac [Bayer Ag – Germany]

News

August 16, 2021

[Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study](#)

:: Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA backbone

:: Data demonstrate high protective efficacy of second-generation lead candidate, CV2CoV, in animal model during SARS-CoV-2 challenge study

:: Neutralizing capacity of induced antibodies tested against a range of variants, including the Beta, Delta and Lambda variant

Gamaleya National Center

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China

Home - - [Website not responding at inquiry; receiving 502 Bad Gateway]

Janssen/JNJ

Press Releases

Statement on Boosting with the Johnson & Johnson COVID-19 Vaccine

NEW BRUNSWICK, N.J., August 18, 2021 -- We are engaging with the U.S. FDA, CDC and other health authorities and will share new data shortly regarding boosting with the Johnson & Johnson COVID-19 vaccine.

In July, Johnson & Johnson shared data demonstrating that our single-shot COVID-19 vaccine generated strong, persistent immune activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. Interim results from a Phase 1/2a study published in the New England Journal of Medicine also showed that the durability of the immune response was strong, with no waning for at least eight months, the length of time that had been evaluated to date. Ensuring long-term and durable protection against hospitalization and death are critical in curbing the COVID-19 pandemic.

Moderna

Press Releases

August 16, 2021

Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna's COVID-19 Vaccine in 2022, in 2023 and in 2024

Novavax

Press Releases - No new digest announcements identified

Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance

Aug 16, 2021

Pfizer

Recent Press Releases

08.16.2021

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

:: Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust immune responses

:: The booster dose elicited significantly higher neutralizing antibody titers against the initial SARS-CoV-2 virus (wild type), and the Beta and Delta variants, compared to the levels observed after the two-dose primary series

:: After the booster dose, neutralizing titers for variants were similar to wild type

:: Given the high levels of immune responses observed, a booster dose given within 6 to 12 months after the primary vaccination schedule may help maintain a high level of protection against COVID-19

Sanofi Pasteur

Press Releases - No new digest announcements identified

Serum Institute of India

NEWS & ANNOUNCEMENTS

SCHOTT and Serum Institute of India Announce Joint Venture for Pharmaceutical Packaging

Serum Institute of India (SII) acquires 50% stake of SCHOTT Kaisha to become SCHOTT's joint venture partner and secure pharma packaging supply
17 August 2021

Sinopharm/WIBPBIBP

News - No new digest announcements identified

Sinovac

Press Releases - No new digest announcements identified

Vector State Research Centre of Virology and Biotechnology

Home - No new digest announcements identified

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

.....

GSK

Press releases for media

16 August 2021

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

:: Preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac's first-generation mRNA backbone

:: Data demonstrates high protective efficacy of second-generation lead candidate, CV2CoV, in animal model during SARS-CoV-2 challenge study

:: Neutralizing capacity of induced antibodies tested against a range of variants, including the Beta, Delta and Lambda variant

SK Biosciences

Press releases - No new digest announcements identified

.....

.....

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 21 Aug 21

An overview of information collected from publicly announced bilateral and multilateral supply agreements [agreements view since last week's edition]



22

vaccines approved for use by at least one national regulatory authority ¹



7

vaccines in WHO's Emergency Use Listing



18.3bn

doses secured globally



\$2 - \$37

reported vaccine price range per dose



5.09bn

doses COVAX has secured, optioned, or received as donations



209.8M

doses shipped through COVAX to 138 countries

Deal date	Country/territory/group	Deal type	Vaccine developer	Manufacturer
8/1/2021	Libya	Bilateral	Sinopharm (Beijing)	Sinopharm
8/2/2021	El Salvador	Bilateral	Sinopharm (Beijing)	Sinopharm
8/5/2021	Mauritius	Bilateral	Gamaleya Research Institute	Gamaleya

.....
.....

Duke – Launch and Scale Speedometer

The Race for Global COVID-19 Vaccine Equity

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)


.....
.....

Global Dashboard on COVID-19 Vaccine Equity

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 21 Aug 21]: <https://data.undp.org/vaccine-equity/>

See also visualization on [Vaccine Access](#) and [Vaccine Affordability](#)






Our World in Data

Coronavirus (COVID-19) Vaccinations [Accessed 21 Aug 21]

- [32.3%](#) of the world population has received at least one dose of a COVID-19 vaccine, and [24.3%](#) is fully vaccinated.
- [4.91 billion doses](#) have been administered globally, and [34.96 million](#) are now administered each day.
- Only [1.4%](#) of people in low-income countries have received at least one dose.




COVID-19 vaccine doses administered per 100 people, Aug 20, 2021

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses per 100 people can be higher than 100.

Our World
in Data

LINEAR LOG

+ Add country



Source: Official data collated by Our World in Data - Last updated 21 August 2021, 12:30 (London time)
OurWorldInData.org/coronavirus • CC BY


Dec 2, 2020 Aug 20, 2021

Share of the population fully vaccinated against COVID-19, Aug 20, 2021

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

Our World
in Data

+ Add country



Source: Official data collated by Our World in Data - Last updated 21 August 2021, 12:30 (London time)

Note: This data is only available for countries which report the breakdown of doses administered by first and second doses. Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

Dec 27, 2020 Aug 20, 2021

.....
.....

U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

August 18, 2021

Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration's plan for COVID-19 booster shots for the American people.

The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissioner, Food and Drug Administration (FDA); Dr. Vivek Murthy, U.S. Surgeon General; Dr. Francis Collins, Director of the National Institutes of Health (NIH); Dr. Anthony Fauci, Chief Medical Advisor to President Joe Biden and Director of the National Institute of Allergy and Infectious Diseases (NIAID); Dr. Rachel Levine, Assistant Secretary for Health; Dr. David Kessler, Chief Science Officer for the COVID-19 Response; and Dr. Marcella Nunez-Smith, Chair of the COVID-19 Health Equity Task Force:

"The COVID-19 vaccines authorized in the United States continue to be remarkably effective in reducing risk of severe disease, hospitalization, and death, even against the widely circulating Delta variant. Recognizing that many vaccines are associated with a reduction in protection over time, and acknowledging that additional vaccine doses could be needed to provide long lasting protection, we have been analyzing the scientific data closely from the United States and around the world to understand how long this protection will last and how we might maximize this protection. The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the Delta variant, we are starting to see evidence of reduced protection against mild and moderate disease. Based on our latest assessment, the current protection against severe disease, hospitalization, and death could diminish in the months ahead, especially among those who are at higher risk or were vaccinated during the earlier phases of the vaccination rollout. For that reason, we conclude that a booster shot will be needed to maximize vaccine-induced protection and prolong its durability.

"We have developed a plan to begin offering these booster shots this fall subject to FDA conducting an independent evaluation and determination of the safety and effectiveness of a third dose of the Pfizer and Moderna mRNA vaccines and CDC's Advisory Committee on Immunization Practices (ACIP) issuing booster dose recommendations based on a thorough review of the evidence. We are prepared to offer booster shots for all Americans beginning the week of September 20 and starting 8 months after an individual's second dose. At that time, the individuals who were fully vaccinated earliest in the vaccination rollout, including many health care providers, nursing home residents, and other seniors, will likely be eligible for a booster. We would also begin efforts to deliver booster shots directly to residents of long-term care facilities at that time, given the distribution of vaccines to this population early in the vaccine rollout and the continued increased risk that COVID-19 poses to them.

"We also anticipate booster shots will likely be needed for people who received the Johnson & Johnson (J&J) vaccine. Administration of the J&J vaccine did not begin in the U.S. until March 2021, and we

expect more data on J&J in the next few weeks. With those data in hand, we will keep the public informed with a timely plan for J&J booster shots as well.

"Our top priority remains staying ahead of the virus and protecting the American people from COVID-19 with safe, effective, and long-lasting vaccines especially in the context of a constantly changing virus and epidemiologic landscape. We will continue to follow the science on a daily basis, and we are prepared to modify this plan should new data emerge that requires it.

"We also want to emphasize the ongoing urgency of vaccinating the unvaccinated in the U.S. and around the world. Nearly all the cases of severe disease, hospitalization, and death continue to occur among those not yet vaccinated at all. We will continue to ramp up efforts to increase vaccinations here at home and to ensure people have accurate information about vaccines from trusted sources. **We will also continue to expand our efforts to increase the supply of vaccines for other countries, building further on the more than 600 million doses we have already committed to donate globally."**

.....

Editor's Note:

We assess [1] the announcement of a plan as above to provide booster doses of COVID vaccines with an established start date – *before* FDA action and *before* a CDC decision to accept a supporting recommendation from an ACIP meeting not yet held, and [2] concluding the announcement of such a plan by referencing continuing but unspecified efforts "to increase the supply of vacancies for other countries" to be incongruous.

.....

Vaccines and Related Biological Products Advisory Committee- FDA

:: No meetings scheduled

.....

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

Remarks by President Biden on Fighting the COVID-19 Pandemic

August 18, 2021 • Speeches and Remarks

Memorandum on Ensuring a Safe Return to In-Person School for the Nation's Children

August 18, 2021 • Presidential Actions

FACT SHEET: President Biden to Announce New Actions to Protect Americans from COVID-19 and Help State and Local Leaders Fight the Virus

August 18, 2021 • Statements and Releases

...Today the President will highlight the following actions:

Planning to Offer COVID-19 Booster Shots Starting the Week of September 20:

Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) announced a plan for administering booster shots later this fall, pending final Food and Drug Administration (FDA) evaluation and recommendations from the Centers for Disease Control and

Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP). Under this plan, a booster would be administered, eight months after an individual's second dose, beginning the week of September 20—at which point those individuals who were fully vaccinated earliest in the vaccination rollout will be eligible, including many health care providers, nursing home residents, and other seniors...We will also continue to expand our efforts to send vaccines to other countries, building on the more than 600 million doses we have already committed to donate globally...

[Press Briefing by White House COVID-19 Response Team and Public Health Officials](#)

August 18, 2021 • Press Briefings

.....
.....

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

[News: EMA starts evaluating use of RoActemra in hospitalised adults with severe COVID-19 \(new\)](#)

CHMP, Last updated: 16/08/2021

[Artificial intelligence in medicine regulation](#)

News 16/08/2021

The International Coalition of Medicines Regulatory Authorities (ICMRA) sets out recommendations to help regulators to address the challenges that the use of artificial intelligence (AI) poses for global medicines regulation, in a report published today.

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

Latest Updates

News

.....



European Centre for Disease Prevention and Control


COVID-19 Vaccine Tracker

Number of adults (18+) with at least one dose in EU/EEA	Number of full vaccinations among adults (18+) in EU/EEA
277,532,117	241,536,076

Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA
74.9%	65.2%


Cumulative number of vaccine doses administered to adults (18+) in EU/EEA countries as of 2021-08-20

by reporting week (data for current week are preliminary)



Cumulative uptake (%) of at least one vaccine dose and full vaccination among adults (18+) in EU/EEA countries as of 2021-08-20

by reporting week (data for the current week are preliminary)



Data as of 2021-08-14

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

.....

European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 20 August 2021

Coronavirus: EU makes available additional humanitarian funding of €41 million to fight the pandemic

The EU will provide €41 million to help low and middle-income countries facing an unprecedented health, humanitarian and socio-economic crisis as the COVID-19 pandemic continues to persist, combined with the imbalance in the delivery of vaccines.


Press release 16 August 2021

Coronavirus: 13 European countries provide urgent assistance to Tunisia

To help Tunisia cope with the impact of the COVID-19 pandemic and the worrying health situation within the country, the European Union and its member states continue to mobilise emergency aid via the EU Civil Protection Mechanism.

.....
.....

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment



Vaccines received from COVAX

47
Countries

Vaccines received bilaterally

45
Countries

Vaccines received from AVATT

20
Countries

Current at 08/11/2021 Full scale, interactive dashboard available at:
<https://africacdc.org/covid-19-vaccination/>

.....
.....

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Russia: Sputnik V – "the first registered COVID-19 vaccine"

<https://sputnikvaccine.com/newsroom/pressreleases/>

Press Releases

[A combination between AstraZeneca and the first component of Sputnik V vaccine \(Sputnik Light\) demonstrates high immunogenicity profile during the clinical study in Azerbaijan](#)

Press release, 20.08.2021

Real-world data shows one shot Sputnik Light vaccine (the first component of the Sputnik V vaccine) has high safety and 93.5% efficacy against COVID during vaccination in Paraguay

Press release, 17.08.2021

.....
.....

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Ministry of Health and Family Welfare

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :
21 August 2021, 08:00
IST (GMT+5:30)

(↑↓ Status change since
yesterday)

Active (1.12%)

361340 (2265↓)

Discharged (97.54%)

31597982 (36347↑)

Deaths (1.34%)

433964 (375↑)

COVID-19 Vaccination
as on : 21 August
2021, 08:00 IST
(GMT+5:30)

Total Vaccination : 57,61,17,350 (36,36,043↑)

Latest Updates

17.08.2021

Genomic Surveillance for SARS-CoV-2 In India: Indian SARS-CoV-2 Genomics Consortium (INSACOG) (Updated guidelines and SOPs)

... Indian SARS-CoV-2 Genomics Consortium (INSACOG) was established to expand Whole Genome Sequencing of SARS-CoV-2 across the nation, aiding our understanding of how the virus spreads and evolves. The Consortium had initially started with a network of ten regional genome sequencing laboratories spread across the country and has now been expanded to currently include 28 INSACOG Genome Sequencing Laboratories (IGSLs) that are mapped to the States and UTs for facilitating smooth flow of samples. The viral genome sequencing data generated by these IGSLs is analysed by the respective centres and sent to the National Centre for Disease Control (NCDC), Delhi for collation and integration...

Government of India – Press Information Bureau

Latest Press Releases

The approval for world's first DNA based 'ZyCov-D' vaccine of Zydus Universe is a testimony to the innovative zeal of India's scientists: PM

Posted on: 20 Aug 2021

The Prime Minister, Shri Narendra Modi has said that the approval for world's first DNA based 'ZyCov-D' vaccine of is a testimony to the innovative zeal of India's scientists.

In response to a tweet by CDSCO India Info, the Prime Minister said; "India is fighting COVID-19 with full vigour. The approval for world's first DNA based 'ZyCoV-D' vaccine of @ZydusUniverse is a testimony to the innovative zeal of India's scientists. A momentous feat indeed."

[CDSCO INDIA INFO @CDSCO INDIA INF](#)

[Aug 20](#)

After evaluation of interim Phase III clinical trial results in consultation with Subject Expert Committee, CDSCO has approved DNA COVID-19 vaccine (ZyCoV-D) of M/s Cadila Healthcare for restricted use in emergency situation in India for 12 years and above.

.....

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world

:: World's first Plasmid DNA Vaccine for COVID-19, ZyCoV-D will be administered in three doses.

:: Apart from adults, for the first time adolescents in the age group of 12-18 years will take the vaccine shot in India.

:: Safety, efficacy and immunogenicity of the vaccine is well established.

:: Company begins stockpiling of the vaccine.

Ahmedabad, August 20, 2021,

Zydus Cadila today announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world's first Plasmid DNA Vaccine for COVID-19. ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day. With this approval, India now has its first COVID-19 vaccine for the adolescents in the 12-18 age group, besides the adult population. ZyCoV-D, is a needle-free vaccine administered using The PharmaJet® a needle free applicator, which ensures painless intradermal vaccine delivery.

This is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use. The platform because of its rapid plug and play technology can be easily adapted to deal with mutations in the virus, such as those already occurring. The company plans to manufacture 10-12 crore doses of ZyCoV-D annually.

Speaking on this development, Mr. Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said "This is a historic milestone with ZyCoV-D, a product of Indian innovation becoming the world's first DNA vaccine being offered for human use and supporting the world's largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against COVID-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years. I would like to thank all the researchers, clinical trial investigators, volunteers and the regulators who have supported this endeavour."

The company also plans to seek approval for the two dose regimen of the vaccine. The main advantage of DNA vaccines is their ability to stimulate both the humoral and cellular arms of the adaptive immune system. They are a valuable form of antigen-specific immunotherapy, as they are safe, stable and can be easily produced. Zydus acknowledges the support of National Biopharma Mission, BIRAC, Department of Biotechnology, Govt of India, National Institute of Virology, Indian Council of Medical Research and PharmaJet® in the development of ZyCoV-D vaccine...

.....

Indian Council for Medical Research (ICMR)

<https://www.icmr.gov.in/media.html>

Press Releases

[India achieves milestone of 50 crores COVID-19 Sample Testing](#)

19/08/2021

.....
.....

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

[see China CDC below]

.....
.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

[Polio this week as of 17 August 2021](#)

:: The Global Polio Eradication Initiative (GPEI) is closely monitoring developments in Afghanistan. GPEI partners and staff are currently assessing immediate disruptions to polio eradication efforts and the delivery of other essential health services, to ensure continuity of surveillance and immunization activities while prioritizing the safety and security of staff and frontline health workers in the country. [Read more...](#)

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):

:: Pakistan: One WPV1 positive environmental sample
:: Madagascar: One cVDPV2 positive environmental sample
:: Nigeria: 26 cVDPV2 cases

.....

[Statement of the Twenty-Ninth Polio IHR Emergency Committee](#)

20 August 2021

The twenty-ninth meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 4 August 2021 with committee members and advisers attending via video conference, supported by the WHO Secretariat. The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV). The following IHR States Parties provided an update at the video conference on the current situation in their respective countries: Afghanistan, China, Democratic Republic of the Congo, Egypt, Madagascar, Nigeria, Pakistan and Uganda.,,

...Conclusion

Although heartened by the apparent progress, the Committee unanimously agreed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern (PHEIC) and recommended the extension of Temporary Recommendations for a further three months. The Committee recognizes the concerns regarding the lengthy duration of the polio PHEIC, but concludes that the current situation remains risky, with clear ongoing risk of international spread and ongoing need for coordinated international responses. The Committee also recognised that the ongoing COVID-19 pandemic may have an adverse impact on polio surveillance and on immunisation activities, as will the gradual withdrawal of polio funds from some of the affected countries...

... Additional considerations

The Committee welcomed the substantial progress that has been made but **warned that the situation in Afghanistan risked a rapid reversal of progress.** The Committee urged the polio programme to continue to discuss with all parties involved to ensure every missed child in inaccessible areas be quickly brought up to date with vaccines to avoid a sudden surge in cases, particularly as the high season commences. The Committee also urged donors and partners to continue their support, noting the beneficial use of polio assets during the pandemic and that **a critical juncture had been reached: decreasing funding by governments, partly as a result of the pandemic, risked all the hard won gains being lost.**

The Committee also welcomed the roll-out of novel OPV2 but was concerned to hear of delays in outbreak response, in some cases as countries preferred to wait for novel OPV2. Polio outbreaks should continue to be met with a suitable sense of urgency, and response time generally needed to be reduced. The Committee requested the polio programme to continue to assist countries to mount an emergency response with whichever vaccine formulation was available.

The Committee also warned of the ongoing effects of COVID-19, particularly on routine immunization, and possible future disruptions of supply and delivery of vaccines. COVID-19 is likely to continue to have negative effects on all health programs and systems for some time to come, so the polio programme must continue to adjust its response on an ongoing basis to get over the remaining hurdles.

Based on the current situation regarding WPV1 and cVDPV, and the reports provided by affected countries, the **Director-General accepted the Committee's assessment and on 10 August 2021 determined that the situation relating to poliovirus continues to constitute a PHEIC,** with respect to WPV1 and cVDPV. The Director-General endorsed the Committee's recommendations for countries meeting the definition for 'States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread', 'States infected with cVDPV2 with potential risk for international spread' and for 'States no longer infected by WPV1 or cVDPV, but which remain vulnerable to re-infection by WPV or cVDPV' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective 10 August 2021.

.....
.....

WHO/OCHA Emergencies

Editor's Note:

WHO has apparently reorganized and fundamentally shifted how it judges and tracks "emergencies". We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list - WHO

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

Crisis in Tigray, Ethiopia *[Last apparent update: 5 Aug 2021]*

Ebola outbreak, Democratic Republic of the Congo, 2021

:: 17 August 2021 News release Cote d'Ivoire starts Ebola vaccination of frontline workers

Ebola outbreak outbreak, N'Zerekore, Guinea, 2021

:: 17 August 2021 News release Cote d'Ivoire starts Ebola vaccination of frontline workers

Coronavirus disease (COVID-19) pandemic *[See COVID above]*

Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020

:: 17 August 2021 News release Cote d'Ivoire starts Ebola vaccination of frontline workers

Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020

:: 17 August 2021 News release Cote d'Ivoire starts Ebola vaccination of frontline workers

Ebola outbreak, Democratic Republic of the Congo, 2018 *[Last apparent update: 24 July 2018]*

Yemen crisis *[Last apparent update: 12 February 2021]*

Syria crisis *[Last apparent update: 18 June 2021]*

Somalia crisis *[Last apparent update: 24 March 2018]*

Nigeria crisis *[Last apparent update: 9 May 2018]*

Ebola outbreak, Democratic Republic of the Congo, 2017 *[Last apparent update: 3 May 2021]*

:: 17 August 2021 News release Cote d'Ivoire starts Ebola vaccination of frontline workers

Zika virus disease outbreak, 2015-2016 *[Last apparent update: 24 Jan 2020]*

Ebola outbreak: West Africa, 2014-2016

:: 17 August 2021 News release Cote d'Ivoire starts Ebola vaccination of frontline workers

Iraq crisis *[Last apparent update: 9 Jan 2008]*

South Sudan crisis *[Last apparent update: 23 Sep 2020]*

[Avian influenza A \(H7N9\) virus outbreak](#) *[Last apparent update: 21 May 2021]*

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) *[Last apparent update: 8 July 2019]*

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) *[Last apparent update: 10 Aug 2010]*

.....

[UN OCHA – Current Emergencies](#)

Current Corporate Emergencies

Northern Ethiopia

[Ethiopia Humanitarian Bulletin Issue #11 2 – 16 August 2021](#)

.....

.....

WHO & Regional Offices [to 21 Aug 21]

<https://www.who.int/>

News

20 August 2021

Statement

[Statement of the Twenty-Ninth Polio IHR Emergency Committee](#)

[See Polio above for detail]

20 August 2021

News release

[Call for experts to join Scientific Advisory Group for the Origins of Novel Pathogens](#)

[See COVID above for detail]

19 August 2021

Joint News Release

[Bucharest, Cairo, Córdoba, Dublin, Greater Manchester, and Warsaw Join Bloomberg Philanthropies' Partnership for Healthy Cities](#)

19 August 2021

Statement

[Statement by Principals of the Inter-Agency Standing Committee \(IASC\) on Afghanistan](#)

18 August 2021

Statement

[Joint Statement from Unitaid and the World Health Organization \(on behalf of the Access to COVID-19 Tools Accelerator\) regarding availability of tocilizumab](#)

18 August 2021

Departmental news

[Social Listening: Finding the Signal Through the Noise](#)

18 August 2021

Departmental news

[New WHO Publication: Infodemic Signal Detection During the COVID-19 Pandemic](#)

17 August 2021

News release

[Cote d'Ivoire starts Ebola vaccination of frontline workers](#)

16 August 2021

News release

[ACT-Accelerator launches urgent US\\$ 7.7 billion appeal to stem surge of dangerous variants and save lives everywhere](#)

[See COVID above for detail]

16 August 2021

Medical product alert

[Medical Product Alert N°5/2021: Falsified COVISHIELD vaccine](#)

16 August 2021

Departmental news

[Neglected tropical diseases: enhancing safe treatment for more than 1 billion people annually](#)

14 August 2021

News release

[PAHO deploys experts to support Haiti during earthquake aftermath](#)

14 August 2021

News release

[Cote d'Ivoire declares first Ebola outbreak in more than 25 years](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: [WHO support to countries rolling out multiple COVID-19 vaccines](#) 19 August 2021

With 620 million COVID-19 vaccine doses set to arrive in Africa through COVAX alone by the end of 2021, African countries are set to roll out a range of different vaccines, each with their own unique storage, transport and administration requirements.

:: [Meet team WHO: Dr Gilson Paluku, Immunization Officer](#) 19 August 2021

A medical doctor with experience in over 15 countries in Africa and the Americas, Dr Paluku was Chief Medical Officer for North Kivu province in his native Democratic Republic of Congo (DRC) before joining the World Health Organization (WHO) back in 2001.

:: [Togo vaccinates over 90% of health workers against COVID-19](#) 19 August 2021

:: [Learning from Botswana's COVID-19 vaccine rollout](#) 19 August 2021

Africa's largest-ever vaccination drive is well underway.⁵² African countries are rolling out COVID-19 vaccines and over 73 million doses have been administered on the continent.

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

No new digest content identified

WHO Eastern Mediterranean Region EMRO

:: Statement on Afghanistan by Dr Ahmed Al-Mandhari, WHO Regional Director for the Eastern Mediterranean

:: Joint statement on the occasion of World Humanitarian Day 19 August 2021

:: More than 40 000 doses of AstraZeneca COVID-19 vaccine, donated by Malta, arrive in Libya 18 August 2021

:: Race against time to boost COVID-19 vaccine uptake in Somalia 17 August 2021

:: Egypt receives third batch of AstraZeneca vaccines through the COVAX Facility 16 August 2021

WHO Western Pacific Region

No new digest content identified

.....

New WHO Publications [Selected]

<https://www.who.int/publications/i>

Using multidimensional poverty and vulnerability indices to inform equitable policies and interventions in health emergencies

17 August 2021 | *Scientific brief*

Overview

To prevent or mitigate the health equity impacts of health emergencies, or the health dimensions of humanitarian emergencies, analysts and decision-makers require an evidence-base to inform equitable planning, policy making, and interventions. In addition to several existing emergencies rapid assessment tools, multidimensional poverty and vulnerability indices (MPIs or MVIs) have been used for measurement, analyses, and policy guidance in several countries around the world. This research brief provides an overview of the use of MPIs and MVIs in health emergencies, with the goal of sharing insights and lessons learned. This brief shares experiences from Afghanistan, Colombia, Honduras, Iraq, and select countries in southern Asia. This research brief will also inform national health authorities when looking for ways to reinforce health equity into their measurement approaches in their policies before, during and after a health emergency.

PDF: <https://apps.who.int/iris/rest/bitstreams/1363839/retrieve>

.....
.....

CDC/ACIP [U.S.] [to 21 Aug 21]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

Wednesday, August 18, 2021

[See COVID above for detail]

CDC Stands Up New Disease Forecasting Center

Wednesday, August 18, 2021

Today, the Centers for Disease Control and Prevention (CDC) is announcing a new center designed to advance the use of forecasting and outbreak analytics in public health decision making. Once established, the Center for Forecasting and Outbreak Analytics will bring together next-generation public health data, expert disease modelers, public health emergency responders, and high-quality communications, to meet the needs of decision makers. The new center will accelerate access to and use of data for public health decision-makers who need information to mitigate the effects of disease threats, such as social and economic disruption. The center will prioritize equity and accessibility, while serving as a hub for innovation and research on disease modeling...

... The new leadership team charged with the development and implementation of a plan to establish the center, includes:

- :: Dr. Marc Lipsitch, who will serve as Director for Science
- :: Dr. Dylan George, who will serve as Director for Operations
- :: Dr. Caitlin Rivers, who will serve as Associate Director
- :: Dr. Rebecca Kahn, who will serve as Senior Scientist

... In establishing the center, CDC is addressing a critical need to improve the U.S. government's ability to forecast and model emerging health threats, while building on existing modeling activities, expanding collaboration through interoperability, accessibility and increased emphasis on policy-maker decision support and communication to the public.

.....

CDC-ACIP

Meeting - August 30-31, 2021, 10:00 a.m. – 4:00 p.m. is a virtual COVID-19 meeting.

No registration is required.

[Webcast](#) [No agenda identified on ACIP pages]

.....

MMWR News Synopsis Friday, August 20, 2021

:: Disparities in Excess Mortality Associated with COVID-19 — United States, 2020

:: Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities — Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020–March 1, 2021

.....

Coronavirus Disease 2019 (COVID-19)- CDC

Approximately 50 announcements/reports/data summaries.

8/21/21

Overall US COVID-19 Vaccine Distribution and Administration Update as of Sat, 21 Aug 2021 06:00:00 EST

.....
.....

Africa CDC [to 21 Aug 21]

<http://www.africacdc.org/>

News

Press Releases

The Government of Republic of Côte d'Ivoire has declared a case of an Ebola Virus Disease in Abidjan

Addis Ababa, 14 August 2021- the Government of Republic of Côte d'Ivoire has declared the presence of a case of an Ebola virus disease (EVD) infection in the capital city of Abidjan. The case is 18-year-old Guinean girl who travelled from Labe in Guinea to Abidjan by road on 11 August 2021 and hospitalized on the night of 12 August 2021 following a high-grade fever. On the 14th of August 2021, the Institute Pasteur in Cote d'Ivoire confirmed the infection to be EVD. The patient is currently in isolation and under the care of a Treatment Center for Highly Epidemic Diseases at the Treichville University Hospital.

More recently, on 19 June 2021, the Republic of Guinea declared over the EVD outbreak after four months of concerted effort. However, further investigation will be conducted to trace back the relation between this case and the concluded outbreak...

.....
.....

China CDC <http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 21 Aug 21]

<http://en.nhc.gov.cn/>

News

Aug 21: Daily briefing on novel coronavirus cases in China

On Aug 20, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 20 new cases of confirmed infections

National Medical Products Administration – PRC [to 21 Aug 21]

<http://english.nmpa.gov.cn/news.html>

News

China administers cumulative 1.9b vaccine doses

2021-08-20

China had administered more than 1.9 billion COVID-19 vaccine doses as of Wednesday, the National Health Commission said on Aug 19.

CCDC Weekly - Weekly Reports: Current Volume (3)

2021-08-20 / No. 34

[PDF of this issue](#)

- Preplanned Studies: Field Simulation of Aerosol Transmission of SARS-CoV-2 in a Special Building Layout — Guangdong Province, China, 2021

- Methods and Applications: Modelling the Emerging COVID-19 Epidemic and Estimating Intervention Effectiveness — Taiwan, China, 2021
- Methods and Applications: Vaccination Vehicles for COVID-19 Immunization — China, 2021
- Notes from the Field: The First Case of COVID-19 by an A.27 Lineage Variant Detected in a Returning Employee — Sichuan Province, China, January 7, 2021
- Commentary: Guangdong's Study of the Effectiveness of China's Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant

.....

Organization Announcements

Editor's Note:

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 21 Aug 21]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 21 Aug 21]

<https://www.phe.gov/about/barda/Pages/default.aspx>

News

No new digest content identified.

BMGF - Gates Foundation [to 21 Aug 21]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 21 Aug 21]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 21 Aug 21]

<https://carb-x.org/>

News

No new digest content identified.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation [to 21 Aug 21]

<https://centerforvaccineethicsandpolicy.net/>

News/Analysis/Statements

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [NEW] ***Informed Consent: A Monthly Review – August 2021*** is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 21 Aug 21]

<http://cepi.net/>

Latest News

CEPI enters into funding agreement with Gritstone bio to develop COVID-19 variant vaccine

:: CEPI to provide up to US\$20.6 million in funding

:: Funding will support development of a self-amplifying mRNA vaccine candidate against COVID-19 variants

:: Programme forms part of CEPI's efforts to develop "next-generation" COVID-19 vaccines

August 17, 2021; Oslo, Norway—CEPI, the Coalition for Epidemic Preparedness Innovations, today announced that it entered into a funding agreement with Gritstone bio, Inc. to advance development of a self-amplifying mRNA vaccine candidate against COVID-19 variants. CEPI will provide up to US\$20.6 million to support a phase 1 clinical trial, including manufacturing of clinical trial materials as well as supporting preclinical studies and optimisation of manufacturing processes.

This funding forms part of CEPI's programme to develop "next-generation" COVID-19 vaccines that are differentiated from those already in advanced development and can be used against COVID-19 variants. CEPI's portfolio of "next-generation" vaccines currently includes SK bioscience's nanoparticle vaccine candidate (GBP510), the University of Hong Kong's intranasal vaccine candidate, VBI Vaccines' virus-like particle candidate, and ZerunBio's recombinant vaccine candidate...

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 21 Aug 21]

<https://cioms.ch/>

News; Publications

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [to 21 Aug 21]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 21 Aug 21]

<https://dukeghic.org/>

Our Blog

No new digest content identified.

EDCTP [to 21 Aug 21]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

No new digest content identified.

Emory Vaccine Center [to 21 Aug 21]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 21 Aug 21]

<http://www.euvaccine.eu/>

Latest News

[Malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of immune responses](#)

Aug 19, 2021

Original Article: Remarque, E.J., Faber, B.W., Rodriguez Garcia, R. et al. Accelerated phase Ia/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses. npj Vaccines 6, 55 (2021). <https://doi.org/10.1038/s41541-021-00319-2>

Fondation Merieux [to 21 Aug 21]

<http://www.fondation-merieux.org/>

News, Events

Event

[Mérieux Foundation doctorates to present their work during international congresses](#)

August 17, 2021 - Global

Four doctorates' researchers of the Mérieux Foundation have been selected to present their research work on tuberculosis and antimicrobial resistance during international scientific conferences.

Gavi [to 21 Aug 21]

<https://www.gavi.org/>

News Releases

No new digest content identified.

GHIT Fund [to 21 Aug 21]

<https://www.ghitfund.org/newsroom/press>

GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that

No new digest content identified.

Global Fund [to 21 Aug 21]

<https://www.theglobalfund.org/en/news/>

News & Stories

News

Global Fund and Tanzania Deepen Partnership to Fight COVID-19 and Accelerate End of HIV, TB and Malaria

17 August 2021

The Global Fund and the Government of Tanzania are deepening their partnership with new investments to fight the COVID-19 crisis and accelerate the end of the epidemics of HIV, TB and malaria while building resilient and sustainable systems for health.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 21 Aug 21]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 21 Aug 21]

<http://www.hillemanlabs.org/>

Website reports "under maintenance" at inquiry

Human Vaccines Project [to 21 Aug 21]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 21 Aug 21]

<https://www.iavi.org/newsroom>

Latest News

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

ICMRA Informal Innovation Network - Horizon Scanning Assessment Report - Artificial Intelligence

August 16, 2021

The International Coalition of Medicines Regulatory Authorities (ICMRA) published a [report](#) that sets out recommendations to help regulators to address the challenges that the use of artificial intelligence (AI) poses for global medicines regulation.

The report is based on a horizon-scanning exercise, conducted by the ICMRA Informal Network for Innovation working group* and led by the European Medicines Agency (EMA). The goal of this network is to identify challenging topics for medicine regulators, to explore the suitability of existing regulatory frameworks and to develop recommendations to adapt regulatory systems in order to facilitate safe and timely access to innovative medicines.

The implementation of the recommendations will be discussed by ICMRA members in the coming months.

ICRC [to 21 Aug 21]

<https://www.icrc.org/en/whats-new>

Selected News Releases, Statements, Reports

Joint statement on the protection of healthcare

During the recent unrest in parts of South Africa, dozens of medical facilities were destroyed, pharmacies looted, and countless vaccines and other critical medicines were stolen.

19-08-2021 | Statement

Ethiopia: ICRC broadens response to the humanitarian crises

In the first half of 2021, the ICRC's humanitarian activities mainly focused on responding to the humanitarian crisis caused by the fighting in northern Ethiopia and inter-communal clashes in other parts of the country.

17-08-2021 | Article

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 21 Aug 21]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

Africa, Global

Profits trumping humanity when it comes to vaccine equity

In response to the news that vaccines manufactured in South Africa are being exported to Europe, Jagan Chapagain, Secretary General of the International Federation of Red Cross and Red Crescent Societies, said: "We have long been calling for companies to consider manufacturing doses in regions that remain inequitably served of COVID-19 vaccines. That they should then be exported to regions that have vaccinated a majority of their population is incomprehensible. The African continent is still the most underserved in terms of receiving doses — barely 2% of people across the region have been vaccinated. Yet, it is clear that profits are still trumping humanity. If compassion will not open the door to the equitable distribution of COVID-19 vaccine doses, then let it be science, for none of us is safe until we all are. If parts of the world remain unvaccinated, this pandemic will not end."

19 August 2021

Asia Pacific, Cambodia, Indonesia, Laos, Myanmar, Philippines, Thailand, Vietnam

COVID-19: Southeast Asia battles world's highest deaths

Kuala Lumpur/Geneva, 18 August 2021: Southeast Asia is battling the world's highest COVID-19 death toll driven by the Delta variant and unequal global distribution of vaccines. Hospitals remain overwhelmed by record surges across Southeast Asia, from ...
18 August 2021

Institut Pasteur [to 21 Aug 21]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

IOM / International Organization for Migration [to 21 Aug 21]

<http://www.iom.int/press-room/press-releases>

News

Safety of Afghans and Humanitarian Access Must be Top Priorities

2021-08-17 14:58

Geneva – The International Organization for Migration (IOM) has been following with great concern the developments in Afghanistan and the grave consequences for displaced people and civilians needing humanitarian assistance, in a country already severely affected by years of...

IOM Supports Response to Earthquake in Haiti

2021-08-16 20:03

Port-au-Prince – As Haiti struggles to cope in the aftermath of a deadly weekend earthquake, the International Organization for Migration's (IOM) relief efforts to support national authorities are now also focusing on finding safe buildings where thousands of displaced residents...

ISC / International Science Council [to 21 Aug 21]

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

<https://council.science/current/>

News

No new digest content identified.

IVAC [to 21 Aug 21]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 21 Aug 21]

<http://www.ivi.int/>

Selected IVI News, Announcements, Events

No new digest content identified.

Johns Hopkins Center for Health Security [to 21 Aug 21]

<https://www.centerforhealthsecurity.org/news/center-news/>

Center News

[Johns Hopkins Center for Health Security Senior Scholar Caitlin Rivers Seconded to the CDC to Help Establish the Center for Epidemic Forecasting and Outbreak Analytics](#)

August 18, 2021

MSF/Médecins Sans Frontières [to 21 Aug 21]

<http://www.msf.org/>

Latest [Selected Announcements]

Central African Republic

[Renewed conflict has displaced hundreds of thousands of people in Central African Republic](#)

Project Update 20 Aug 2021

Afghanistan

[Medical needs urgent as ever in Afghanistan after Taliban takeover](#)

Project Update 18 Aug 2021

Haiti

[Death, destruction and thousands of injured people in wake of Haiti earthquake](#)

Project Update 17 Aug 2021

National Academy of Medicine - USA [to 21 Aug 21]

<https://nam.edu/programs/>

Selected News/Programs

No new digest content identified.

National Academy of Sciences - USA [to 21 Aug 21]

<http://www.nasonline.org/news-and-multimedia/>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 21 Aug 21]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 21 Aug 21]

<http://www.nih.gov/news-events/news-releases>

News Releases

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms

August 18, 2021 — Clinical trial results demonstrate COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients.

NIH hamster study evaluates airborne and fomite transmission of SARS-CoV-2

August 17, 2021 — Findings support efforts to reduce SARS-CoV-2 indoor airborne transmission.

NIH scientists develop faster COVID-19 test

August 16, 2021 — Technique avoids RNA degradation and time-consuming extraction.

PATH [to 21 Aug 21]

<https://www.path.org/media-center/>

Press Releases

No new digest content identified.

Sabin Vaccine Institute [to 21 Aug 21]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

No new digest content identified.

UNAIDS [to 21 Aug 21]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

No new digest content identified.

UNHCR Office of the United Nations High Commissioner for Refugees [to 21 Aug 21]

<http://www.unhcr.org/en-us/media-centre.html>

Selected News Releases, Announcements

UNHCR report: Rohingya refugees, mostly women and children, facing deadlier journeys in the Bay of Bengal and Andaman Sea

19 Aug 2021

UNICEF [to 21 Aug 21]

<https://www.unicef.org/media/press-releases>

Press Releases, News Notes, Statements [Selected]

Press release

08/20/2021

New shipment of UNICEF humanitarian aid arrives in earthquake-struck Haiti

First shipment with medical and water supplies has arrived; more to follow in the coming days

Press release

08/17/2021

Over half a million children affected by Haiti earthquake

Torrential rains are hampering relief efforts

Press release

08/17/2021

Geneva Palais briefing note on the current situation of children in Afghanistan

This is a summary of what was said by UNICEF's Chief of field operations & emergency, Mustapha Ben Messaoud – to whom quoted text may be attributed – at today's press briefing at the Palais des Nations in Geneva.

Unitaid [to 21 Aug 21]

<https://unitaid.org/>

Featured News

18 August 2021

Joint Statement from Unitaid and the World Health Organization (on behalf of the Access to COVID-19 Tools Accelerator) regarding availability of tocilizumab

Geneva, 18 August 2021 – WHO and Unitaid are concerned by Roche's statement yesterday, warning of a global shortage of tocilizumab (brand name Actemra/RoActemra), an IL6 inhibitor WHO recommended in June for use as a treatment for severe COVID-19 cases. Tocilizumab can play a key role in decreasing mortality and reducing need for invasive mechanical ventilation among severely ill patients, when delivered alongside oxygen and corticosteroids.

While we welcome and acknowledge that Roche has announced measures to address the shortage, we call on the company to ensure equitable allocation of current stocks of this medicine for all countries, including low- and middle-income countries.

We also strongly encourage Roche to facilitate technology transfer and knowledge and data sharing to broaden access to this important treatment...

Vaccine Equity Initiative [to 21 Aug 21]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative (Sabin) [to 21 Aug 21]

<https://www.vaccineacceptance.org/>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 21 Aug 21]

<http://www.vaccineconfidence.org/>

News, Research and Reports

Coronavirus global impact

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

Vaccine Education Center – Children’s Hospital of Philadelphia [to 21 Aug 21]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

No new digest content identified.

Wellcome Trust [to 21 Aug 21]

<https://wellcome.ac.uk/news>

News and reports

Opinion

Author: Michael Dunn

[Our new discovery research funding schemes are open for applications](#)

18 August 2021

Michael Dunn explains more about our three new discovery research funding schemes, which are now open for applications.

The Wistar Institute [to 21 Aug 21]

<https://www.wistar.org/news/press-releases>

Press Releases

Aug. 17, 2021

[The BEAT-HIV Collaboratory Receives More Than \\$29 Million in NIH Funding for HIV Cure Research](#)

The collaboratory led by Wistar investigators will continue to test novel combined immunotherapies to advance research towards a cure for HIV.

WFPHA: World Federation of Public Health Associations [to 21 Aug 21]

<https://www.wfpha.org/>

Latest News

[EU Commission’s Response to Co-signed Open Letter on Access to COVID-19 Vaccines and Therapies](#)

Aug 18, 2021

“The Commission is committed to the objective of universal equitable access to vaccines and treatments against COVID-19.”

World Bank [to 21 Aug 21]

<http://www.worldbank.org/en/news/all>

Selected News, Announcements

[Food Security and COVID-19](#)

Aug 17, 2021 – An increasing number of countries are facing growing levels of acute food insecurity, reversing years of development gains. Even before COVID-19 reduced incomes and disrupted supply chains...

Date: August 17, 2021 Type: Brief

[Nepal to Get 4 Million Doses of Moderna Vaccines through COVAX](#)

KATHMANDU, August 13, 2021 – Nepal is the second country globally to have completed agreements with GAVI to procure 4 million doses of Moderna vaccines, financed by the World Bank, through the COVAX...

Date: August 13, 2021 Type: Press Release

World Customs Organization – WCO [to 21 Aug 21]

<http://www.wcoomd.org/>

Latest News – Selected Items

Website not responding at inquiry

World Organisation for Animal Health (OIE) [to 21 Aug 21]

<https://www.oie.int/en/for-the-media/press-releases/2021/>

Press Releases, Statements

No new digest content identified.

WTO - World Trade Organisation [to 21 Aug 21]

http://www.wto.org/english/news_e/news_e.htm

WTO News and Events

No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 21 Aug 21]

[Press Releases - Alliance for Regenerative Medicine \(alliancerm.org\)](#)

Selected Press Releases

[Global Cell & Gene Therapy Sector on Pace for Annual Records in Product Approvals and Financings, Says Alliance for Regenerative Medicine](#)

August 18, 2021 Washington, DC

The regenerative medicine and advanced therapies sector completed its best-ever six-month period of financing, raising \$14.1B from January through June and reaching 71% of the record amount raised in all of 2020, according to the Alliance for Regenerative Medicine's (ARM) [H1 2021 Report](#) released today.

BIO [to 21 Aug 21]

<https://www.bio.org/press-releases>

Press Releases, Letters, Testimony, Comments [Selected]

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 21 Aug 21]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 21 Aug 21]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 21 Aug 21]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

IGBA LAUNCHES A WHITEPAPER: A VISION FOR THE GLOBAL GENERIC AND BIOSIMILAR MEDICINES INDUSTRY

7 July 2021

Today the International Generic and Biosimilar Medicines Association (IGBA) is launching a whitepaper: [A Vision for the Global Generic and Biosimilar Medicines Industry](#), which covers the strong contribution of this pharmaceutical sector to global health outcomes and economies, the opportunities, challenges and disruptions for the industry, its 2030 vision as well as actions needed to achieve this vision... The whitepaper is the result of extensive input from fourteen generic and biosimilar medicines companies and IGBA member associations, and supports the global recovery efforts to rethink, build and secure a future which addresses the inequalities in healthcare, while supporting sustainability...

International Alliance of Patients' Organizations – IAPO [to 21 Aug 21]

<https://www.iapo.org.uk/news/topic/6>

Press and media [Selected]

No new digest content identified.

PhRMA [to 21 Aug 21]

<http://www.phrma.org/>

Latest News [Selected]

No new digest content identified.

*

*

*

*

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some

editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 12, 2020 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 23, Number 8: E597-665 Aug 2021

<https://journalofethics.ama-assn.org/issue/economic-decision-modeling-health-care>

Economic Decision Modeling in Health Care

Rising health care costs in the United States have created the need to identify prevention and treatment strategies that are both effective and economical. Decision modeling studies aim to help policy makers, organizational leaders, and clinicians quantify and compare prospective costs and benefits of interventions in standardized ways. But health care system operations, patients' behaviors, and clinicians' behaviors are extremely complex and hard to accurately predict. Good analysis of what models yield requires identifying which assumptions should shape clinical practice decisions and patients' health care experiences.

[Reviewed earlier]

American Journal of Infection Control

August 2021 Volume 49 Issue 8p973-1092

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

August 2021 Volume 61 Issue 2 p149-310

<https://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

July 2021 111(52)

<http://ajph.aphapublications.org/toc/ajph/current>

Supplement 2 2021

When Dying Really Counts

This new fully Open Access supplement issue looks at the urgent need to improve the quality of mortality data and routine surveillance in the context of COVID-19 and beyond. Consequences of inaccuracies in mortality data threaten the mission of public health, while challenges facing the professions of those who encounter and study death are facing unprecedented pressures

American Journal of Tropical Medicine and Hygiene

Volume 105 (2021): Issue 2 (Aug 2021)

<https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml>

EDITORIAL

Short-term and Potentially Long-term Negative Impacts of COVID-19 in Sub-Saharan Africa: Evidence from the Africa Research, Implementation Science, and Education Network Rapid Monitoring Survey

Davidson H. Hamer

PERSPECTIVE PIECES

Equitable and Feasible Distribution of SARS-CoV-2 Vaccines for All in Africa

Abu Bakarr Rogers, Mohamed Bailor Barrie, Mosoka P. Fallah, and J. Daniel Kelly

ARTICLES

Global Health Partnerships During the COVID-19 Pandemic: Perspectives and Insights from International Partners

Megan S. McHenry, Reena P. Tam, Amira A. Nafiseh, Mary Ann Etling, Adelaide E. Barnes, Amy R. L. Rule, Heather L. Crouse, Heather Haq, Lee E. Morris, Brittany L. Murray, Lisa A. Umphrey, and Elizabeth M. Keating

DOI: <https://doi.org/10.4269/ajtmh.21-0156>

Annals of Internal Medicine

July 2021 Volume 174, Issue 7

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 297 August 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/297/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 21 Aug 21)

[No new digest content identified]

BMJ Global Health

August 2021 - Volume 6 - Suppl 5

https://gh.bmj.com/content/6/Suppl_5

Digital Innovations for Community and Primary Health in India

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 21 Aug 21)

[Designing an SMS reminder intervention to improve vaccination uptake in Northern Nigeria: a qualitative study](#)

Penta3 coverage in Nigeria was low at 33 % in 2017. The most reported reason for non-vaccination was lack of knowledge about the immunization place, time, and need. To address knowledge gaps and improve vaccin...

Authors: Chisom Obi-Jeff, Cristina Garcia, Obinna Onuoha, Funmi Adewumi, Winnie David, Tobi Bamiduro, Abdulrasheed Bello Aliyu, Alain Labrique and Chizoba Wonodi

Citation: BMC Health Services Research 2021 21:844

Content type: Research

Published on: 20 August 2021

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 21 Aug 21)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 21 Aug 21)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 21 Aug 21)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 21 Aug 21)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 21 Aug 21)

[Trends and determinants of vaccination among children aged 06–59 months in Bangladesh: country representative survey from 1993 to 2014](#)

Vaccination has important consequences for childhood development, mortality, and inequalities in health and well-being. This research explores the trend of vaccinations coverage from 1993 to 2014 and determine...

Authors: Md. Moyazzem Hossain, Md. Abdus Sobhan, Azizur Rahman, Sanzida Sharmin Flora and Zahida Sultana Irin
Citation: BMC Public Health 2021 21:1578
Content type: Research article
Published on: 21 August 2021

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>
(Accessed 21 Aug 21)
[No new digest content identified]

BMJ Evidence-Based Medicine

August 2021 - Volume 26 - 4
<https://ebm.bmj.com/content/26/4>
[Reviewed earlier]

BMJ Open

August 2021 - Volume 11 - 8
<https://bmjopen.bmj.com/content/11/8>
[Reviewed earlier]

Bulletin of the World Health Organization

Volume 99(8); 2021 Aug 1
<https://www.ncbi.nlm.nih.gov/pmc/issues/386733/>
[Reviewed earlier]

Cell

Aug 19, 2021 Volume 184 Issue 17 p4373-4596
<https://www.cell.com/cell/current>
Articles

[Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses](#)

Anusha Nathan, ET AL.

Structure-based network analyses identify regions in the SARS-CoV-2 proteome that are mutationally constrained and bear CD8+ T cell epitopes that are also conserved in emerging variants as well as other sarbecoviruses. These epitopes elicit stronger CD8+ T cell responses in convalescent individuals over mRNA vaccine recipients and provide a framework for a broad T-cell-based vaccine against coronaviruses.

Child Care, Health and Development

Volume 47, Issue 5 Pages: 575-731 September 2021
<https://onlinelibrary.wiley.com/toc/13652214/current>
[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 110, Issue 2 Pages: 263-518 August 2021
<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>
[Reviewed earlier]

Clinical Therapeutics

Volume 43 Issue 4 p651-792
<http://www.clinicaltherapeutics.com/current>
[Reviewed earlier]

Clinical Trials

Volume 18 Issue 4, August 2021
<https://journals.sagepub.com/toc/ctja/18/4>
[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>
[Accessed 21 Aug 21]
[No new digest content identified]

Contemporary Clinical Trials

Volume 106 July 2021
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/106/suppl/C>
[Reviewed earlier]

The CRISPR Journal

Volume 4, Issue 4 / August 2021
<https://www.liebertpub.com/toc/crispr/4/4>
Perspective Open Access

[Governing Heritable Human Genome Editing: A Textual History and a Proposal for the Future](#)

LeRoy Walters, Robert M. Cook-Deegan, and Eli Y. Adashi

Pages:469–476

Published Online:16 August 2021

<https://doi.org/10.1089/crispr.2021.0043>

Abstract

Heritable human genome editing (HHGE) has become a topic of intense public interest, especially since 2015. In the early 1980s, a related topic—human genetic engineering—was the subject of sustained public discussion. There was particular concern about germline genetic intervention. During the 1980s debate, an advisory committee to the Director of the National Institutes of Health (NIH)—the Recombinant DNA Advisory Committee (RAC)—agreed to provide initial public review of proposals for

deliberate introduction of DNA into human beings. In 1984 and 1985, the RAC developed guidelines for research involving DNA transfer into patients. The committee also commented on the possibility of deliberately altering the human germline. We track the textual changes over time in the RAC's response to the possibility of germline genetic intervention in humans. In 2019, the NIH RAC was abolished. New techniques for genome editing, including CRISPR-based techniques, make both somatic and germline alterations much more feasible. These novel capabilities have again raised questions about oversight. We propose the creation of a new structure for the public oversight of proposals to perform HHGE. In parallel with a technical review by a regulatory agency, such proposals should also be publicly evaluated by a presidentially appointed Bioethics Advisory Commission.

Review Article

[Application of CRISPR-Cas9 Editing for Virus Engineering and the Development of Recombinant Viral Vaccines](#)

Na Tang, Yaoyao Zhang, Zhiqiang Shen, Yongxiu Yao, and Venugopal Nair

Pages:477–490

Published Online:16 August 2021

<https://doi.org/10.1089/crispr.2021.0017>

Review Article

[Application of CRISPR-Cas9 Editing for Virus Engineering and the Development of Recombinant Viral Vaccines](#)

Na Tang, Yaoyao Zhang, Zhiqiang Shen, Yongxiu Yao, and Venugopal Nair

Pages:477–490

Published Online:16 August 2021

<https://doi.org/10.1089/crispr.2021.0017>

Abstract

The advent of human gene editing has stimulated international interest in how best to govern this research. However, research on stakeholder views has neglected scientists themselves. We surveyed 212 scientists who use gene editing in their work. Questions captured views on oversight and use of somatic and germline human gene editing for treatment, prevention, and enhancement. More respondents were supportive of somatic than germline editing, and more supported gene editing for treatment compared to prevention. Few supported its use for enhancement. When presented with specific conditions, levels of support for somatic editing differed by type of condition. Almost all respondents said scientists and national government representatives should be involved in oversight, but only 28% said scientists are best positioned to oversee gene-editing research. These results can inform the development of sound approaches to research governance, demonstrating the importance of identifying specific gene-editing uses when considering oversight.

Current Genetic Medicine Reports

Volume 9, issue 3, September 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

August 2021 - Volume 34 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Current Protocols in Human Genetics

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

Developing World Bioethics

Volume 21, Issue 2 June 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

Special Issue: Conscientious objection to termination of pregnancy in the global south: legal and ethical challenges

Issue Edited by: Anita Kleinsmidt

Development in Practice

Volume 31, Issue 5, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness

Volume 15 - Issue 3 - June 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 45, Issue 3 Pages: 499-737 July 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 22 Issue 8 4 August 2021

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 27, Number 7—July 2021

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 35 June 2021

<https://www.sciencedirect.com/journal/epidemics/vol/35/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 149 - 2021

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 43, Issue 4 Pages: 1-44 July–August 2021

<https://onlinelibrary.wiley.com/toc/25782363/current>

[Reviewed earlier]

The European Journal of Public Health

SUPPLEMENT - Volume 31, Issue Supplement_1, July 2021

https://academic.oup.com/eurpub/issue/31/Supplement_1

Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders' Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

Mental illness represents an enormous personal, social and societal burden for European citizens¹ calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,² and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications ('eHealth'³ and 'm-Health'⁴) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders^{5,6} and meta-analyses show effect sizes similar to face-to-face interventions.⁷

Expert Review of Vaccines

Vol 20 (5) 2021

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Forum for Development Studies

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 21 Aug 21]

[No new digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 21 Aug 21]

[No new digest content identified]

Global Health Action

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 9, No. 2 June 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Legal Monitor – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 21 Aug 21]

[No new digest content identified]

Global Public Health

Volume 16, Issue 8-9 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

Politics and pandemics

This Special Issue of Global Public Health on Politics & Pandemics brings together 26 articles and commentaries that address diverse aspects of the politics of COVID-19 and related issues. These papers are grouped together in six topical areas: theories and politics of global health, health systems and policies, country responses, social inequalities, social responses, and the politics of science and technology. The goal of the Special Issue is to give readers a sense of the range of topics that have been a focus for research in relation to the COVID-19 pandemic and to provide diverse examples of how research and analysis on the political dimensions of the pandemic can contribute to confronting the COVID-19 crisis.

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 21 Aug 21]

[No new digest content identified]

Health Affairs

Vol. 40, No. 7 July 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

July 2021 / Borders, Immigrants & Health

About one in seven residents of the US is an immigrant, and about fifteen million people live within 100 kilometers of the US-Mexico border. Disparities in health status exist between people born in the US and those who have immigrated. Immigration policy has been contentious throughout US history, and current policies in the US and Mexico have significant effects on the health and well-being of tens of millions of people. This thematic issue of *Health Affairs* focuses on immigrants and borders. The overview article by Arturo Vargas Bustamante and coauthors describes a range of health policy issues raised by the continuously shifting demography of US immigrants.

Health and Human Rights

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

Special Section: Mental Health and Human Rights

[Reviewed earlier]

Health Economics, Policy and Law

Volume 16 - Issue 3 - July 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 36, Issue 6, July 2021

<https://academic.oup.com/heapol/issue/36/6>

ORIGINAL ARTICLES

[Health gains and financial protection from human papillomavirus vaccination in Ethiopia: findings from a modelling study](#)

Allison Portnoy, Steven Sweet, Dawit Desalegn, Solomon Tessema Memirie, Jane J Kim ...

REVIEWS

[Implementing 'universal' access to antiretroviral treatment in South Africa: a scoping review on research priorities](#)

Hanlie Myburgh, Lindsey Reynolds, Graeme Hoddinott, Dianne van Aswegen, Nelis Grobbelaar ...

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 21 Aug 21]

[Reviewed earlier]

Human Gene Therapy

Volume 32, Issue 15-16 / August 2021

<https://www.liebertpub.com/toc/hum/32/15-16>

[New issue; No digest content identified]

Humanitarian Exchange Magazine

Number 79, May 2021

<https://odihpn.org/magazine/localisation-and-local-humanitarian-action/>

Localisation and local humanitarian action

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 17, Issue 5, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 21 Aug 21]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournals.com/content>

[Accessed 21 Aug 21]

Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein

Authors: Jiluo Liu, Xi Chen, Yan Liu, Jiansheng Lin, Jiaying Shen, Hongwei Zhang, Jianhua Yin, Rui Pu, Yibo Ding and Guangwen Cao

Content type: Research Article

21 August 2021

International Health

Volume 13, Issue 4, July 2021

<https://academic.oup.com/inthealth/issue/13/4>

[Reviewed earlier]

International Human Rights Law Review

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 8, No 8 (2021) August 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/79>

[Reviewed earlier]

International Journal of Epidemiology

Volume 50, Issue 3, June 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

July 2021 Volume 108 p1-616

<https://www.ijidonline.com/current>

[Reviewed earlier]

JAMA

August 17, 2021, Vol 326, No. 7, Pages 587-680

<https://jamanetwork.com/journals/jama/currentissue>

Racial and Ethnic Disparities and Inequities in Medicine and Health Care

Viewpoint

[Partnering With the Faith-Based Community to Address Disparities in COVID-19](#)

[Vaccination Rates and Outcomes Among US Black and Latino Populations](#)

Anthony Evans, MDiv; Joseph Webster, MD; Glenn Flores, MD

free access

JAMA. 2021;326(7):609-610. doi:10.1001/jama.2021.12652

This Viewpoint discusses the low rates at which Black and Latino individuals in the US are being vaccinated against COVID-19 and how the National Black Church Initiative plans to address gaps in vaccination as well as other health care disparities.

JAMA Network**[COVID-19 Update August 21, 2021](#)**

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

August 2021, Vol 175, No. 8, Pages 766-876

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

July 2021 - Volume 19 - Issue 7

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

August 2021 Volume 69 Issue 2 p181-356

<https://www.jahonline.org/current>

[New issue; No digest content identified]

Journal of Artificial Intelligence Research

Vol. 71 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 46, issue 4, August 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-4>

[Reviewed earlier]

Journal of Development Economics

Volume 152 September 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/152/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 16 Issue 3, July 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

July 2021 - Volume 75 - 7

<https://jech.bmj.com/content/75/7>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 14, Issue 2 Pages: 83-169 May 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 3, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 32, Number 2, May 2021 Supplement

<https://muse.jhu.edu/issue/44396>

Table of Contents

[Overview of the Issue](#)

Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark

...The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.

This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care...

Journal of Immigrant and Minority Health

Volume 23, issue 4, August 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-4>

[New issue; No digest content identified]

Journal of Immigrant & Refugee Studies

Volume 19, 2021_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 224, Issue 2, 15 July 2021

<https://academic.oup.com/jid/issue/224/2>

[Reviewed earlier]

Journal of Medical Ethics

August 2021 - Volume 47 - 8

<http://jme.bmj.com/content/current>

[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 8, Issue 3 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

Journal of Pediatrics

August 2021 Volume 235 p1-306

<http://www.jpeds.com/current>

[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>

[Accessed 21 Aug 21]

[No new digest content identified]

Journal of Public Health Management & Practice

July/August 2021 - Volume 27 - Issue 4

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 42, issue 2, June 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-2>

[Reviewed earlier]

Journal of Refugee & Global Health

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

Journal of the Royal Society – Interface

August 2021 Volume 18 Issue 181

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 28, Issue 5, July 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 95 Number 16 July 2021

<http://jvi.asm.org/content/current>

[Reviewed earlier]

The Lancet

Aug 21, 2021 Volume 398 Number 10301 p641-724, e10

<https://www.thelancet.com/journals/lancet/issue/current>

Articles

[Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial](#)

Firdausi Qadri, et al.

Open Access

Typhoid fever remains a major cause of morbidity and mortality in low-income and middle-income countries. Vi-tetanus toxoid conjugate vaccine (Vi-TT) is recommended by WHO for implementation in high-burden countries, but there is little evidence about its ability to protect against clinical typhoid in such settings... Vi-TT provided protection against typhoid fever to children vaccinated between 9 months and less than 16 years. Longer-term follow-up will be needed to assess the duration of protection and the need for booster doses.

The Lancet Child & Adolescent Health

Aug 2021 Volume 5 Number 8 p531-604, e28-e31

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Aug 2021 Volume 3 Number 8e 462-e533

<https://www.thelancet.com/journals/landig/issue/current>

[New issue; No digest content identified]

Lancet Global Health

Aug 2021 Volume 9 Number 8 e1028-e1175

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Aug 2021 Volume 21 Number 8 p1051-1192, e208-e257

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

Lancet Public Health

Aug 2021 Volume 6 Number 8 e534-e619

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

Lancet Respiratory Medicine

Aug 2021 Volume 9 Number 8 p803-936, e69-e87

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

Maternal and Child Health Journal

Volume 25, issue 8, August 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-8>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 41 Issue 6, August 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 99, Issue 2 Pages: 329-599 June 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 596 Issue 7872, 19 August 2021

<https://www.nature.com/nature/volumes/596/issues/7872>

Editorial | 17 August 2021

The WHO is right to call a temporary halt to COVID vaccine boosters

Richer countries should focus on ramping up vaccine supply to the billions who are still waiting for their first dose.

Article | 12 July 2021

Systems vaccinology of the BNT162b2 mRNA vaccine in humans

Profiling the immune responses of 56 volunteers vaccinated with BNT162b2 reveals how this mRNA vaccine primes the innate immune system to mount a potent response to SARS-CoV-2 after booster immunization.

Prabhu S. Arunachalam, Madeleine K. D. Scott, Bali Pulendran

Article | 30 June 2021 | Open Access

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Individuals over eighty years of age are less likely to mount a good immune response against SARS-CoV-2 (measured by neutralization titres) after the first dose of the BNT162b2 mRNA vaccine, but achieve good neutralization after the second dose.

Dami A. Collier, Isabella A. T. M. Ferreira, Ravindra K. Gupta

Article | 23 June 2021 | Open Access

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques

SARS-CoV-2 challenge of rhesus macaques demonstrates that the Ad26.COV2.S vaccine induces robust protection against both the WA1/2020 isolate and the B.1.351 variant of concern.

Jingyou Yu, Lisa H. Tostanoski, Dan H. Barouch

Nature Biotechnology

Volume 39 Issue 8, August 2021

<https://www.nature.com/nbt/volumes/39/issues/8>

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 21 Aug 21)

[No new digest content identified]

Nature Genetics

Volume 53 Issue 7, July 2021

<https://www.nature.com/ng/volumes/53/issues/7>

[Reviewed earlier]

Nature Human Behaviour

Volume 5 Issue 7, July 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/7>

[Reviewed earlier]

Nature Medicine

Volume 27 Issue 8, August 2021

<https://www.nature.com/nm/volumes/27/issues/8>

[Reviewed earlier]

Nature Reviews Genetics

Volume 22 Issue 8, August 2021

<https://www.nature.com/nrg/volumes/22/issues/8>

[Reviewed earlier]

Nature Reviews Immunology

Volume 21 Issue 8, August 2021

<https://www.nature.com/nri/volumes/21/issues/8>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 20 Issue 8, August 2021

<https://www.nature.com/nrd/volumes/20/issues/8>

[Reviewed earlier]

New England Journal of Medicine

August 19, 2021 Vol. 385 No. 8

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

[The Covid-19 Infodemic — Applying the Epidemiologic Model to Counter Misinformation](#)

D. Scales, J. Gorman, and K.H. Jamieson

Throughout the world, including the United States, medical professionals and patients are facing both a pandemic and an infodemic — the first caused by SARS-CoV-2 and the second by misinformation and disinformation. The Annenberg Public Policy Center's tracking of social and legacy media has found that millions of people have been exposed to deceptive material alleging that SARS-CoV-2 is a hoax or that experts are exaggerating its severity and the extent of its spread, that masks are ineffective or increase infection risk, or that Covid-19 vaccines cause the disease, alter the recipient's DNA, or include tracking devices. Believing such claims is associated with a lower likelihood of engaging in preventive behavior and a lower willingness to be vaccinated.^{[1](#)}

We believe the intertwining spreads of the virus and of misinformation and disinformation require an approach to counteracting deceptions and misconceptions that parallels epidemiologic models by focusing on three elements: real-time surveillance, accurate diagnosis, and rapid response...

Pediatrics

August 01, 2021; Volume 148, Issue 2

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

PharmacoEconomics

Volume 39, issue 7, July 2021

<https://link.springer.com/journal/40273/volumes-and-issues/39-7>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 21 Aug 21)

[Empowering grassroots innovation to accelerate biomedical research](#)

Bastian Greshake Tzovaras, Michael Rera, Edwin H. Wintermute, Katharina Kloppenborg, Juliette Ferry-Danini, Guy Aidelberg, Rachel Aronoff, Ariel Lindner, Dusan Misevic

Perspective | published 09 Aug 2021 PLOS Biology

<https://doi.org/10.1371/journal.pbio.3001349>

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 21 Aug 21)

[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 21 Aug 21)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

Research Article

[Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia](#)

Auliya Abdurrohman Suwantika, Woro Supadmi, Mohammad Ali, Rizky Abdulah

Research Article | published 12 Aug 2021 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0009664>

PLoS One

<http://www.plosone.org/>

[Accessed 21 Aug 21]

[Peoples' understanding, acceptance, and perceived challenges of vaccination against COVID-19: A cross-sectional study in Bangladesh](#)

Alak Paul, Dwaipayan Sikdar, Janardan Mahanta, Sanjib Ghosh, Md. Akib Javed, Sujat Paul, Fahmida Yeasmin, Suranjana Sikdar, Bishawjit Chowdhury, Tapan Kumar Nath

Research Article | published 20 Aug 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0256493>

Preferences for COVID-19 vaccine distribution strategies in the US: A discrete choice survey

Ingrid Eshun-Wilson, Aaloke Mody, Khai Hoan Tram, Cory Bradley, Alexander Sheve, Branson Fox, Vetta Thompson, Elvin H. Geng

Research Article | published 20 Aug 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0256394>

Improving routine immunization data quality using daily short message system reporting platform: An experience from Nasarawa state, Nigeria

Adekunle Akerere, Belinda Uba, Matthew Aduloju, Sulaiman Etamesor, Jamila A. Umar, Olorunsogo Bidemi Adeoye, Ameh Enyojo, Friday Josiah, Esther Ayandipo, Itse Olaoye, Oluwasegun Joel Adegoke, Sampson Sidney, Murtala Bagana, Okposen Bassey, Margherita E. Ghiselli, Waziri NdadiInasiya, Omotayo Bolu, Faisal Shuaib

Research Article | published 19 Aug 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0255563>

Burden of disease among the world's poorest billion people: An expert-informed secondary analysis of Global Burden of Disease estimates

Matthew M. Coates, Majid Ezzati, Gisela Robles Aguilar, Gene F. Kwan, Daniel Vigo, Ana O. Mocumbi, Anne E. Becker, Julie Makani, Adnan A. Hyder, Yogesh Jain, D. Cristina Stefan, Neil Gupta, Andrew Marx, Gene Bukhman

Research Article | published 16 Aug 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0253073>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 21 Aug 21]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

August 03, 2021; vol. 118 no. 31

<https://www.pnas.org/content/118/32>

[New issue; No digest content identified]

Prehospital & Disaster Medicine

Volume 36 - Issue 4 - August 2021

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 149 August 2021

<https://www.sciencedirect.com/journal/preventive-medicine/vol/149/suppl/C>

Research article Abstract only

Effect of Internet use for searching information on vaccination on the uptake of human papillomavirus vaccine in France: A path-analysis approach

Fadia Dib, Philippe Mayaud, Laetitia Longfier, Pierre Chauvin, Odile Launay

Article 106615

Research article Abstract only

COVID-19 vaccine hesitancy among health care workers in Palestine: A call for action

Beesan Maraqa, Zaher Nazzal, Razan Rabi, Nafez Sarhan, ... Mai Al-Kaila

Article 106618

Proceedings of the Royal Society B

25 August 2021 Volume 288 Issue 1957

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

Public Health

Volume 195 Pages 1-160 (June 2021)

<https://www.sciencedirect.com/journal/public-health/vol/195/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 14, Issue 1, April 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 136 Issue 4, July/August 2021

<https://journals.sagepub.com/toc/phrg/136/4>

[Reviewed earlier]

Qualitative Health Research

Volume 31 Issue 8, July 2021

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

Research Ethics

Volume 17 Issue 3, July 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 21 Aug 21]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Selected Articles

[No new digest content identified]

Risk Analysis

Volume 41, Issue 7 Pages: 1047-1253 July 2021

<https://onlinelibrary.wiley.com/toc/15396924/current>

Special Issue: Interdisciplinary Theory, Methods, and Approaches for Hazards and Disaster Research

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 21 Aug 21]

[No new digest content identified]

Science

20 August 2021 Vol 373, Issue 6557

<http://www.sciencemag.org/current.dtl>

Reports

Malaria infection and severe disease risks in Africa

By Robert S. Paton, Alice Kamau, Samuel Akech, Ambrose Agweyu, Morris Ogero, Charles Mwandawiro, Neema Mturi, Shebe Mohammed, Arthur Mpimbaza, Simon Kariuki, Nancy A. Otieno, Bryan O. Nyawanda, Amina F. Mohamed, George Mtove, Hugh Reyburn, Sunetra Gupta, Philip Bejon, José Lourenço, Robert W. Snow

Science 20 Aug 2021 : 926-931 Full Access

Childhood malaria

Understanding how changes in community parasite prevalence alter the rate and age distribution of severe malaria is essential for optimizing control efforts. Paton et al. assessed the incidence of pediatric severe malaria admissions from 13 hospitals in East Africa from 2006 to 2020 (see the Perspective by Taylor and Slutsker). Each 25% increase in community parasite prevalence shifted hospital admissions toward younger children. Low rates of lifetime infections appeared to confer some immunity to severe malaria in very young children. Children under the age of 5 years thus need to remain a focus of disease prevention for malaria control.

Abstract

The relationship between community prevalence of *Plasmodium falciparum* and the burden of severe, life-threatening disease remains poorly defined. To examine the three most common severe malaria

phenotypes from catchment populations across East Africa, we assembled a dataset of 6506 hospital admissions for malaria in children aged 3 months to 9 years from 2006 to 2020. Admissions were paired with data from community parasite infection surveys. A Bayesian procedure was used to calibrate uncertainties in exposure (parasite prevalence) and outcomes (severe malaria phenotypes). Each 25% increase in prevalence conferred a doubling of severe malaria admission rates. Severe malaria remains a burden predominantly among young children (3 to 59 months) across a wide range of community prevalence typical of East Africa. This study offers a quantitative framework for linking malaria parasite prevalence and severe disease outcomes in children.

Science Translational Medicine

18 August 2021 Vol 13, Issue 607

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

Social Science & Medicine

Volume 284 September 2021

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/284/suppl/C>

[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 21 Aug 21]

[Enrollment, retention, and strategies for including disadvantaged populations in randomized controlled trials: a systematic review protocol](#)

Many randomized controlled trials fail to reach their target sample size. When coupled with the omission and underrepresentation of disadvantaged groups in randomized controlled trials, many trials fail to obtain data that accurately represents the true diversity of their target population. Policies and practices have been implemented to increase representation of disadvantaged groups in many randomized controlled trials, with some trials specifically targeting such groups. To our knowledge, no systematic review has quantified the enrollment metrics and effectiveness of inclusion and retention strategies in randomized controlled trials focused on disadvantaged populations specifically.

Authors: Abigail LaPlante, Renata W. Yen, Talia Isaacs, Joanna Crocker, Zsofia Demjen, Danielle Schubbe, Alice M. Kennedy, Jaclyn Engel, Nancy O'Brien, Carla Richters and Marie-Anne Durand

Citation: Systematic Reviews 2021 10:233

Content type: Protocol

Published on: 18 August 2021

Theoretical Medicine and Bioethics

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 42 July–August 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/42/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 26, Issue 7 Pages: i-iv, 715-837 July 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 39, Issue 32 Pages 4391-4570 (22 July 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/32>

Review article Abstract only

Promoting, seeking, and reaching vaccination services: A systematic review of costs to immunization programs, beneficiaries, and caregivers

Tatenda T. Yemeke, Elizabeth Mitgang, Patrick T. Wedlock, Colleen Higgins, ... Sachiko Ozawa

Pages 4437-4449

Research article Open access

Safety and immunogenicity of two formulations of rotavirus vaccine in Vietnamese infants

V.D. Thiem, D.D. Anh, V.H. Ha, N.D. Hien, ... N. Rathi

Pages 4463-4470

Research article Abstract only

Vaccine hesitancy among hospital staff physicians: A cross-sectional survey in France in 2019

Pierre Verger, Christian Dualé, Nezha Lenzi, Dimitri Scronias, ... Odile Launay

Pages 4481-4488

Value in Health

August 2021 Volume 24 Issue 8 p1089-1236

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

* * * *

Think Tanks et al

Brookings [to 21 Aug 21]

<http://www.brookings.edu/>

Report

A proposal for long-term COVID-19 control

Universal vaccination, prophylactic drugs, rigorous mitigation, and international cooperation

William A. Haseltine

Friday, August 20, 2021

...In this paper, I propose a multimodal strategy for long-term COVID control, one that sets up multiple barriers of protection so that we are able to not only contain SARS-CoV-2 and eliminate COVID-19 as a major life-threatening disease, but also return to a new social and economic life. The strategy uses the best of what we have on hand today—a rapidly growing arsenal of vaccines and antiviral drugs and public health measures— with an eye towards future improvements and developments...

Center for Global Development [to 21 Aug 21]

<http://www.cgdev.org/page/press-center>

The Challenge of Reallocating SDRs: A Primer

Publication

August 18, 2021

The approval of a new allocation of Special Drawing Rights (SDRs) by the International Monetary Fund (IMF) is the first effort to deal with the financial impact of the COVID-19 crisis on a global level. The purpose of this note is to reframe the concept of SDRs and then to outline in broad the types of proposals that have been mooted as a basis for more detailed work over the coming months.

Retooling UNICEF: New Leadership Needs to Couple Humanitarian Imperatives with Systems Reform

August 16, 2021

UNICEF's Executive Director, Henrietta Fore, recently announced that she will step down from her position. With a change in leadership imminent, we consider the organization's dual imperative: to protect children during humanitarian crises - including the current COVID-19 crisis-, and to shift from direct service delivery towards support for systems and policies that will drive sustainable improvements in child well-being today and tomorrow.

[Amanda Glassman](#) and [Sudhanshu Handa](#)

Chatham House [to 21 Aug 21]

<https://www.chathamhouse.org/>

Accessed 21 Aug 21

[No new digest content identified]

CSIS

<https://www.csis.org/>

Accessed 21 Aug 21

Podcast Episode

Insuring Quality Vaccines during a Global Pandemic

August 19, 2021 | By Katherine E. Bliss

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

August 19, 2021 *News Release*

Four in Ten Parents of School-Aged Children Say a Child Fell Behind Academically Due to the COVID-19 Pandemic

Four in Ten Parents Say Someone in Their Household Left a Job or Worked Fewer Hours to Care for Their Children, Including Higher Shares of Black, Hispanic, and Lower-income Parents As a result of the pandemic, about four in ten (39%) parents of school-aged children (ages 5-17) say at least...

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute , PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *